**表1到7，用户选择数字，系统自动生成文字描述。表8，展示自定义数字阈值(≥xx%),系统按列找到数值大于这个阈值的AE，生成句子，AE按降序描述。**

**Subject information:**

Table 1: Subject Disposition - All Treated Analysis Set

Table 2: Subjects with Major Protocol Deviation; All Treated Analysis Set

Table 3: Study Drug Expose; All Treated Analysis Set

**Efficacy Results:**

Table 4: Progression Free Survival; All Treated Analysis Set

Table 5: Duration of Response based on IRC Assessment; Responders in All Treated Analysis Set

Table 6: Time to Disease Progression based on IRC Assessment; All Treated Analysis Set

**Safety Results:**

Table 7: Overview of Treatment-emergent Adverse Events; All Treated Analysis Set

Table 8: Incidence of Treatment-emergent Adverse Events Occurring in 10% or More Subjects in Either Group by Preferred Term, and Maximum Toxicity Grade (这个表用来做自定义数字阈值找AE的展示)

**Table of Content:**

Table 1: Subject Disposition - All Treated Analysis Set 2

Table 2: Subjects with Major Protocol Deviation; All Treated Analysis Set 2

Table 3: Study Drug Expose; All Treated Analysis Set 3

Table 4: Progression Free Survival; All Treated Analysis Set 4

Table 5: Duration of Response based on IRC Assessment; Responders in All Treated Analysis Set……………………………..…………………………………………………………………..5

Table 6: Time to Disease Progression based on IRC Assessment; All Treated Analysis Set….5

Table 7: Overview of Treatment-emergent Adverse Events; All Treated Analysis Set 6

**Table 8:** **Incidence of Treatment-emergent Adverse Events Occurring in 10% or More Subjects in Either Group by Preferred Term, and Maximum Toxicity Grade** 7

| Table 1: Subject Disposition - Treatment; All Treated Analysis Set | | | |
| --- | --- | --- | --- |
|  | 8 mg/kg | 16 mg/kg | Total |
| Analysis set: all treated | 18 | 106 | 124 |
| **Discontinued from treatment** | **16 (88.9%)** | **90 (84.9%)** | **106 (85.5%)** |
| Progressive disease | 16 (88.9%) | 82 (77.4%) | 98 (79.0%) |
| Adverse event | 0 | 5 (4.7%) | 5 (4.0%) |
| Withdrawal of consent | 0 | 3 (2.8%) | 3 (2.4%) |
| Death | 0 | 0 | 0 |
| Percentages are calculated with the number of subjects in each group as denominator. | | | |
| Modified from Attachment TSIDS01 | | | |

| Table 2: Subjects with Major Protocol Deviation; All Treated Analysis Set | | | |
| --- | --- | --- | --- |
|  | 8 mg/kg | 16 mg/kg | Total |
| Analysis set: all treated | 18 | 106 | 124 |
|  |  |  |  |
| **Subjects with major protocol deviation** | **2 (11.1%)** | **9 (8.5%)** | **11 (8.9%)** |
| Received wrong treatment or incorrect dose | 0 | 3 (2.8%) | 3 (2.4%) |
| Received a disallowed concomitant treatment | 0 | 0 | 0 |
| Entered but did not satisfy criteria | 2 (11.1%) | 5 (4.7%) | 7 (5.6%) |
| Developed withdrawal criteria but not withdrawn | 0 | 0 | 0 |
| Efficacy assessment deviation | 0 | 0 | 0 |
| Safety assessment deviation | 0 | 0 | 0 |
| Other\* | 0 | 1 (0.9%) | 1 (0.8%) |
| \* Screening ECG was not done for this subject.  Percentages are calculated with the number of subjects in each group as denominator. | | | |
| Modified from Attachment TSIPD01 | | | |

| Table 3: Daratumumab Infusions; All Treated Analysis Set | | | |
| --- | --- | --- | --- |
|  | 8 mg/kg | 16 mg/kg | Total |
| Analysis set: all treated | 18 | 106 | 124 |
|  |  |  |  |
| Duration of treatment (months) |  |  |  |
| N | 18 | 106 | 124 |
| Mean (SD) | 3.745 (4.5922) | 4.252 (3.3556) | 4.178 (3.5439) |
| Median | 1.873 | 2.825 | 2.793 |
| Range | (0.03; 13.90) | (0.03; 14.19) | (0.03; 14.19) |
|  |  |  |  |
| Number of treatment cycles |  |  |  |
| N | 18 | 106 | 124 |
| At least 1 cycle | 18 (100.0%) | 106 (100.0%) | 124 (100.0%) |
| At least 2 cycles | 16 (88.9%) | 96 (90.6%) | 112 (90.3%) |
| At least 3 cycles | 10 (55.6%) | 79 (74.5%) | 89 (71.8%) |
| At least 4 cycles | 8 (44.4%) | 61 (57.5%) | 69 (55.6%) |
| At least 5 cycles | 4 (22.2%) | 45 (42.5%) | 49 (39.5%) |
| At least 6 cycles | 4 (22.2%) | 40 (37.7%) | 44 (35.5%) |
| At least 7 cycles | 4 (22.2%) | 34 (32.1%) | 38 (30.6%) |
| Mean (SD) | 5.0 (4.95) | 5.3 (3.73) | 5.3 (3.91) |
| Median | 3.0 | 4.0 | 4.0 |
| Range | (1; 16) | (1; 16) | (1; 16) |
|  |  |  |  |
| Total dose received (mg/kg) |  |  |  |
| N | 18 | 106 | 124 |
| Mean (SD) | 51.96 (65.056) | 198.63 (97.009) | 177.34 (106.346) |
| Median | 24.26 | 176.01 | 163.33 |
| Range | (7.7; 216.1) | (1.9; 416.8) | (1.9; 416.8) |
|  |  |  |  |
| Total number of Daratumumab infusions |  |  |  |
| N | 18 | 106 | 124 |
| Mean (SD) | 5.2 (5.23) | 12.4 (6.06) | 11.4 (6.46) |
| Median | 3.0 | 11.0 | 11.0 |
| Range | (1; 16) | (1; 26) | (1; 26) |
|  |  |  |  |
| Relative dose intensity (%) |  |  |  |
| N | 18 | 106 | 124 |
| Mean (SD) | 97.48 (9.995) | 99.15 (8.669) | 98.90 (8.849) |
| Median | 99.96 | 100.02 | 100.01 |
| Range | (58.1; 103.6) | (11.7; 103.5) | (11.7; 103.6) |
| Note: 3 subjects in the 8 mg/kg group crossed to the 16 mg/kg group and results for these 3 subjects are included in the 8 mg/kg treatment group. Percentages are calculated with the number of subjects in each group as denominator. A subject is considered as treated in a cycle if he/she received any nonzero dose of Daratumumab in that cycle. | | | |
| Modified from Attachment TSIEXP01 | | | |

| Table 4: Progression Free Survival based on IRC Assessment; All Treated Analysis Set | | |
| --- | --- | --- |
|  | 8 mg/kg | 16 mg/kg |
| Analysis set: all treated | 18 | 106 |
| Progression-free survival |  |  |
| Number of events (%) | 6 (33.3%) | 75 (70.8%) |
| Number of censored (%) | 12 (66.7%) | 31 (29.2%) |
| Kaplan-Meier estimate (months) |  |  |
| 25% quantile (95% CI) | 1.87 (0.99, 4.86) | 1.61 (0.95, 1.97) |
| Median (95% CI) | 4.86 (1.84, NE) | 3.65 (2.76, 4.63) |
| 75% quantile (95% CI) | NE (3.32, NE) | 7.66 (6.47, NE) |
| 3-month progression free survival rate % (95% CI) | 63.5 (28.9, 84.7) | 50.2 (39.8, 59.6) |
| 6-month progression free survival rate % (95% CI) | 25.4 (1.6, 63.7) | 36.7 (27.0, 46.4) |
| 12-month progression free survival rate % (95% CI) | 25.4 (1.6, 63.7) | 18.3 (10.7, 27.5) |
| Keys: IRC = independent review committee; CI = confidence interval; NE = not estimable. Note: Percentages are calculated with the number of subjects in each group as denominator. | | |
| [TEFPFS01A.rtf] [JNJ-54767414\MMY2002\DBR\_CSR\RE\_CSR\tefpfs01a.sas] 13FEB2015, 14:39 | | |

| Table 5: Duration of Response based on IRC Assessment; Responders in All Treated Analysis | |
| --- | --- |
|  | 16 mg/kg |
| Analysis set: responders in all treated | 31 |
| Duration of response |  |
| Number of events (%) | 17 (54.8%) |
| Number of censored (%) | 14 (45.2%) |
| Kaplan-Meier estimate (months) |  |
| 25% quantile (95% CI) | 4.0 (1.9, 5.6) |
| Median (95% CI) | 7.4 (5.5, NE) |
| 75% quantile (95% CI) | NE (7.5, NE) |
| 3-month duration of response rate % (95% CI) | 87.1 (69.2, 95.0) |
| 6-month duration of response rate % (95% CI) | 59.2 (39.3, 74.5) |
| 12-month duration of response rate % (95% CI) | 37.8 (19.6, 55.9) |
| Keys: IRC = independent review committee; CI = confidence interval; NE = not estimable. Percentages are calculated with the number of subjects in each group as denominator. | |
| Modified from Attachment TEFDOR01A | |

| Table 6: Time to Disease Progression based on IRC Assessment; All Treated Analysis Set | | |
| --- | --- | --- |
|  | 8 mg/kg | 16 mg/kg |
| Analysis set: all treated | 18 | 106 |
|  |  |  |
| Time to disease progression |  |  |
| Number of events (%) | 6 (33.3%) | 73 (68.9%) |
| Number of censored (%) | 12 (66.7%) | 33 (31.1%) |
|  |  |  |
| Kaplan-Meier estimate (months) |  |  |
| 25% quantile (95% CI) | 1.87 (0.99, 4.86) | 1.84 (0.95, 2.33) |
| Median (95% CI) | 4.86 (1.84, NE) | 3.71 (2.79, 5.39) |
| 75% quantile (95% CI) | NE (3.32, NE) | 7.66 (6.51, NE) |
|  |  |  |
| 3-month disease progression free rate % (95% CI) | 63.5 (28.9, 84.7) | 51.2 (40.7, 60.7) |
| 6-month disease progression free rate % (95% CI) | 25.4 (1.6, 63.7) | 37.4 (27.6, 47.2) |
| 12-month disease progression free rate % (95% CI) | 25.4 (1.6, 63.7) | 18.7 (11.0, 28.0) |
| Keys: IRC = independent review committee; CI = confidence interval; NE = not estimable. Note: Percentages are calculated with the number of subjects in each group as denominator. | | |
| [TEFTTP01A.rtf] [JNJ-54767414\MMY2002\DBR\_CSR\RE\_CSR\tefttp01a.sas] 13FEB2015, 14:37 | | |

| Table 7: Overview of Treatment-emergent Adverse Events; All Treated Analysis Set | | | | | |
| --- | --- | --- | --- | --- | --- |
|  | | 16 mg/kg | | |  |
|  | 8 mg/kg | Part 1 | Part 2 | Total | Total |
| **Analysis set: all treated** | **18** | **41** | **65** | **106** | **124** |
|  |  |  |  |  |  |
| Any TEAE | 18 (100.0%) | 40 (97.6%) | 65 (100.0%) | 105 (99.1%) | 123 (99.2%) |
| Drug-related | 14 (77.8%) | 27 (65.9%) | 54 (83.1%) | 81 (76.4%) | 95 (76.6%) |
|  |  |  |  |  |  |
| Any serious TEAE | 6 (33.3%) | 11 (26.8%) | 21 (32.3%) | 32 (30.2%) | 38 (30.6%) |
| Drug-related | 0 | 2 (4.9%) | 6 (9.2%) | 8 (7.5%) | 8 (6.5%) |
|  |  |  |  |  |  |
| Maximum severity of any TEAE |  |  |  |  |  |
| Grade 1 | 2 (11.1%) | 5 (12.2%) | 3 (4.6%) | 8 (7.5%) | 10 (8.1%) |
| Grade 2 | 5 (27.8%) | 5 (12.2%) | 21 (32.3%) | 26 (24.5%) | 31 (25.0%) |
| Grade 3 | 8 (44.4%) | 22 (53.7%) | 26 (40.0%) | 48 (45.3%) | 56 (45.2%) |
| Grade 4 | 3 (16.7%) | 4 (9.8%) | 10 (15.4%) | 14 (13.2%) | 17 (13.7%) |
| Grade 5 | 0 | 4 (9.8%) | 5 (7.7%) | 9 (8.5%) | 9 (7.3%) |
|  |  |  |  |  |  |
| Treatment discontinuation due to TEAEa | 0 | 1 (2.4%) | 4 (6.2%) | 5 (4.7%) | 5 (4.0%) |
| Drug-related | 0 | 0 | 0 | 0 | 0 |
|  |  |  |  |  |  |
| Death due to TEAEb | 0 | 1 (2.4%) | 1 (1.5%) | 2 (1.9%) | 2 (1.6%) |
| Drug-related | 0 | 0 | 0 | 0 | 0 |
| Keys: TEAE = treatment-emergent adverse event.  aTreatment discontinuation due to adverse event on the end of treatment CRF page.  bDeath due to adverse event on the death CRF page. Percentages are calculated with the number of subjects in each group as denominator. | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 8: Incidence of Treatment-emergent Adverse Events Occurring in 10% or More Subjects in Either Group by Preferred Term, and Maximum Toxicity Grade** | | | | | | |
| Group: Overall | | | | | | |
|  | -------------- Med A Group ------------- | | | -------------- Control Group ------------- | | |
|  | (N=104) | | | (N=52) | | |
|  | All Grades | - Toxicity Grade, n (%) - | | All Grades | - Toxicity Grade, n (%) - | |
| Dictionary-Derived Term | n (%) | Grade 3+4 | Grade 5 n (%) | | Grade 3+4 | Grade 5 |
| **Total no. subjects with any treatment-emergent adverse events** | 103 (99.0) |  |  | 47 (90.4) |  |  |
|  |  |  |  |  |  |  |
| Diarrhoea | 34 (32.7) | 4 (3.8) | 0 | 3 (5.8) | 0 | 0 |
| Platelet count decreased | 30 (28.8) | 8 (7.7) | 0 | 14 (26.9) | 3 (5.8) | 0 |
| Neutrophil count decreased | 28 (26.9) | 19 (18.3) | 0 | 20 (38.5) | 12 (23.1) | 0 |
| Pyrexia | 26 (25.0) | 1 (1.0) | 0 | 14 (26.9) | 1 (1.9) | 0 |
| Cough | 25 (24.0) | 1 (1.0) | 0 | 4 (7.7) | 0 | 0 |
| Neutropenia | 23 (22.1) | 17 (16.3) | 0 | 11 (21.2) | 10 (19.2) | 0 |
| Rash | 23 (22.1) | 0 | 0 | 3 (5.8) | 0 | 0 |
| Fatigue | 20 (19.2) | 0 | 0 | 6 (11.5) | 0 | 0 |
| Lung infection | 20 (19.2) | 16 (15.4) | 0 | 6 (11.5) | 5 (9.6) | 0 |
| Upper respiratory tract infection | 20 (19.2) | 6 (5.8) | 0 | 6 (11.5) | 1 (1.9) | 0 |
| Thrombocytopenia | 17 (16.3) | 5 (4.8) | 0 | 3 (5.8) | 0 | 0 |
| Anaemia | 15 (14.4) | 1 (1.0) | 0 | 6 (11.5) | 0 | 0 |
| Haemoglobin decreased | 15 (14.4) | 0 | 0 | 6 (11.5) | 0 | 0 |
| Nausea | 15 (14.4) | 0 | 0 | 1 (1.9) | 0 | 0 |
| Constipation | 12 (11.5) | 0 | 0 | 0 | 0 | 0 |
| Leukocytosis | 12 (11.5) | 12 (11.5) | 0 | 0 | 0 | 0 |
| Mouth ulceration | 12 (11.5) | 0 | 0 | 2 (3.8) | 0 | 0 |
| Vertigo | 12 (11.5) | 0 | 0 | 0 | 0 | 0 |
| White blood cell count decreased | 6 (5.8) | 2 (1.9) | 0 | 8 (15.4) | 3 (5.8) | 0 |
| Chills | 1 (1.0) | 0 | 0 | 9 (17.3) | 0 | 0 |
| Note: A subject with multiple severity ratings for a given AE was counted only once under the maximum toxicity grade. | | | | | | |
| Note: Subjects with missing toxicity grades are included in All Grades column but not shown separately. | | | | | | |
| Note: Adverse events are presented by descending frequency of PT within All Grades for Ibrutinib; those with the same frequency are presented alphabetically. | | | | | | |
| Note: Percentages are calculated with the number of subjects in the safety analysis set in each treatment group as denominators. | | | | | | |
| Note: Adverse events were coded using MedDRA Version 18.0. | | | | | | |
|  | | | | | | |